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ABSTR ACT: Studies linking vitamin D and long-term metabolic health have generated much debate. Recommendations for the intake of vitamin D by 
the general public and by the health care professionals have been complicated by a number of inconsistencies in the literature. These caveats relate to the 
methodological approaches, differences in the populations (and the species) of study, and the definitions used for thresholds of vitamin D status. This review 
addresses current evidence available for assessing the potential programming of long-term metabolic health of offspring by maternal vitamin D status in 
pregnancy. It summarizes knowledge on the early origins of metabolic health and analyzes evidence for an association between the vitamin D status in 
pregnancy and maternal and fetal health status. In addition, we analyze the link between the regulation of inflammation and the vitamin D status in the 
general population to inform on the general mechanisms through which early vitamin D might affect the programming of long-term health. The evidence 
suggests an association between the vitamin D status in early life and the programming of long-term health. However, to the best of our knowledge, the 
current finding is insufficient to draw a final conclusion for evidence-based preventive actions. The data warrant replication in prospective studies and addi-
tional research substantiating the causal factors and pathways.
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Introduction
The biomedical community is debating the role of vitamin D 
in the etiology of metabolic and cardiovascular ill health. Of 
the 30 leading causes of death in the US, 19 have been linked 
to the vitamin D status in observational epidemiological stud-
ies, albeit sometimes inconsistently and without the identi-
fication of causal pathways.1 In fact, besides an unequivocal 
role of vitamin D in the calcium metabolism, bone growth, 
and prevention of rickets and osteomalacia, much uncertainty 
remains. Lower vitamin D status, ideally defined by serum 
concentration of 25-hydroxyvitamin D [25(OH)D], has 
been reported to associate with impaired metabolic function 
in adults, including higher risk of obesity, diabetes mellitus 
(type 1 and type 2), and cardiovascular diseases.2–5 The pres-
ent review summarizes the evidence addressing the role of 
vitamin D in the promotion of long-term metabolic health. 
It examines vitamin D in the context of the developmental 
origins of health and diseases paradigm and possible mecha-
nisms through which vitamin D exposure may affect health 
programming. In particular, we review the current evidence 
for a role of maternal vitamin D in pregnancy in the program-
ming of long-term metabolic health and review the knowledge 
on the association between the vitamin D status and the mod-
ulation of systemic inflammation aiming to provide insights 
on the general mechanisms through which vitamin D might 
provoke programming.
Developmental Origins of Cardiometabolic Health
Today, societies worldwide are undergoing important changes 
in the environments surrounding the developmental period. 
The global obesity and diabetes epidemics are accompanied 
by the variation of major metabolic risk factors arising in early 
life and increasing incidence of cases of gestational diabetes 
mellitus (GDM) and maternal obesity (representing 6%–15% 
of all pregnancies).6,7 These metabolic complications affect the 
health of mothers with an increasing risk of direct obstetric 
complications (ie, miscarriage, preterm delivery, and cesar-
ean section) and also raise the risk of long-lasting metabolic 
diseases.8–11 The odds of developing obesity and/or type 2 
diabetes following gestational obesity and diabetes are more 
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than double in comparison to mothers remaining healthy in 
pregnancy.7,9 Moreover, offspring exposed to maternal obesity 
and/or GDM in prenatal life may be more susceptible to early 
onset cardiometabolic adversities. The increased risk observed 
in these offspring may be independent of confounding by 
genetic heritability and nongenetic shared maternal–offspring 
traits (ie, conferral of life style and behavioral factors between 
generations).
There is a compelling evidence on the role of the meta-
bolic factors in early life in programming long-term risk 
of diseases. Epidemiological,12,13 genomical,14 and experi-
mental analyses15,16 are bringing supportive evidence for 
a causal role of early growth performance and the estab-
lishment of cardiometabolic homeostasis throughout life. 
The underlying mechanisms affecting programming of 
metabolic health in the growing fetus are yet to be fully 
understood, but the current research is focusing on deci-
phering both tissue-specific mechanisms as well as the 
potential time-dependency of exposures in determining 
programming.17
Early Life Energetic, Epigenetic, and Trophic 
Remodeling
Alterations in dietary and life style factors are linked to 
dramatic changes in the profiles of metabolic traits.15 This 
affects the metabolic factors in terms of both the amount 
and the type of metabolites that are available to the growing 
fetus as well as the cell signaling machinery and the pro- 
or anti-inflammatory pathways.18 The developmental period 
starting from the periconceptual period and continuing far 
beyond the time of birth is considered as a plastic stage for 
the development of long-term metabolic functions. The 
energy and the macro- and micronutrients available to the 
growing organism act via trophic and epigenetic regulation 
to set some degree of metabolic function.19 All components 
of metabolic homeostasis could be modifiable, and multiple 
examples have suggested that programming occurs in many 
key organs, ie, the liver, kidney, pancreas, adipose tissue(s), 
skeletal muscles, and hypothalamus.20,21 Metabolic stressors 
generated by various early life exposures such as maternal 
overfeeding, intrauterine growth restriction, and maternal 
insulin resistance are associated with the direct modifica-
tions of local and systemic inflammatory responses.17 Both 
the programming of cellular gene expression (via epigen-
etic or other mechanisms) and organ size and function is 
thought to be a direct consequence of altered inflammatory 
balance.22,23
Importance of Critical Windows of Programming
Organogenesis and later fetal development is not a gradual, 
continuous process. There is an evidence for critical windows 
of programming affecting the risk of obesity, hypertension, and 
type 2 diabetes (see Symonds et al19 for review). These windows 
have been observed in the analyses of data from historical birth 
cohorts24,25 and are consistent with an experimental evidence 
from animal models.26 In humans, at least four prenatal 
windows with differential effects are proposed to exist, includ-
ing (i) the periconceptual period with expected imprinting of 
the gametes; (ii) the embryonic period when major changes in 
the methylome occur; (iii) the second trimester of pregnancy 
when key remodeling appears in the hypothalamic and pan-
creatic regions; and (iv) the perinatal period when the fetus is 
experiencing exponential growth. In addition to these prenatal 
stages, observations from animal and human data suggest that 
critical moderating phases after birth could also be important 
programming periods.12 As such, the first month of prenatal 
life, the peak of adiposity accrual, the rebound of adiposity, and 
perhaps also the entry into the pubertal period are representing 
some life course stages where exposures could have pronounced 
and irreversible effects on the long-term metabolic health. 
Each of these stages is essential in setting up neuroendocrine 
pathways and body composition throughout the adulthood.16
Maternal Vitamin D Status and Metabolic 
Complications During Pregnancy
Exposure to maternal vitamin D status in pregnancy has been 
suggested to play a role in programming long-term health 
in offspring. 25(OH)D crosses the maternal–fetal placental 
barrier,27 and at birth, cord blood 25(OH)D concentration is 
linearly associated with maternal 25(OH)D concentration.28,29
Preeclampsia. Preeclampsia characterized by maternal 
endothelial dysfunction, proteinuria, hypertension, and 
impaired placentation affects 2%–8% of the pregnant women 
and is responsible for 25% of maternal deaths worldwide.30,31 
Although low vitamin D status is linked to the incidence 
of preeclampsia, the underlying mechanisms by which 
25(OH)D influence it are unclear.30,31 Two systematic 
reviews and one nested case–control study have concluded 
that women with preeclampsia had lower 25(OH)D and 
calcitriol [1,25(OH)2D3] concentrations in the early preg-
nancy in comparison to normal pregnancy.32–34 Another 
nested case–control study by Achkar et al, based on 169 pre-
eclampsia cases and 1,975 controls, reported a greater odds 
ratio for preeclampsia in women with lower vitamin D status 
(,30  nmol/L) after adjustment for life style and socioeco-
nomic factors.35 Four meta-analyses have also suggested that 
low maternal vitamin D status, with inconsistency on the defi-
nition, is associated with preeclampsia.36–39 A study based on 
isolated syncytiotrophoblasts from normal and preeclamptic 
women observed an inhibition of calcitriol production in pre-
eclampsia patients, linked to a downregulation of 1α hydrox-
ylase gene expression.40 The reason for such low calcitriol 
concentrations in preeclampsia is unknown, as other related 
factors such as calcium, phosphate, and parathyroid hormone 
do not differ significantly between healthy pregnant and pre-
eclamptic women.41–45 These observations suggest a causal link 
between vitamin D status and preeclampsia risk, which might 
in turn affect the fetal health.40,46 Furthermore, circulating 
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insulin-like growth factor 1 (IGF-1) and maternal parathy-
roid hormone-related peptide concentrations are lower in pre-
eclamptic women.47–51 IGF-1 placental mRNA expression and 
IGF-1 concentrations are found to be lower in preeclamptic 
women in comparison to healthy pregnant women.48,52,53 In 
addition to some observed associations of maternal 25(OH)D 
concentration with preeclampsia risk, it is frequently reported 
that preeclampsia can be characterized by an imbalance in the 
systemic circulation of inflammatory cytokines.54–56 In a study 
using flow cytometry to investigate cytokines in healthy and 
preeclamptic women, healthy pregnant women had a lower 
Th1:Th2 ratio and Th1 cell concentration in comparison to 
preeclamptic women.57 This is consistent with another study 
where preeclamptic women were observed to have more a det-
rimental low-grade proinflammatory environment when com-
pared to inflammatory profiles of healthy pregnant women.58 
Some studies have observed that cytokines, such as interleu-
kin 6 (IL-6), tumor necrosis factor-α (TNF-α), IL-2/IL-10, 
IL-15, IL-16, IL-4, IL-18, TNF-α/IL-10, and C-reactive 
protein (CRP) are increased in preeclamptic women when 
compared to women with normal pregnancy.41 Finally, two 
recent meta-analyses have reported that TNF-α, IL-6, and 
IL-10 concentrations are significantly higher in preeclamptic 
women.59,60 It must be noted that so far no study has measured 
the inflammation and the vitamin D status at the same time 
in preeclampsia women to infer a causal link. The evidence so 
far warrants additional research to analyze the moderation of 
the inflammatory status by the vitamin D status to support 
evidence-based preventive action.
Gestational diabetes mellitus. GDM affects 5%–16% 
of the pregnant women in populaces worldwide, depending 
on the diagnostic criteria used.7 GDM is expected to expose 
the fetus to intrauterine hyperglycemia and increased insulin 
secretion in both the mother and offspring exposed to GDM 
and is found to be at higher risk of later development of early 
onset obesity and type 2 diabetes.61–63 A systematic review 
and meta-analysis of seven observational studies reported 
an inverse association between serum 25(OH)D and GDM 
[odds ratio 1.61 (95% CI: 1.19–2.17; P = 0.002)].64 The study 
included 2,146 pregnant women from various countries and 
ethnicities, which resulted in heterogeneity.64 However, 
similar results were observed in other narrative and system-
atic reviews.37,38,65,66 A recent comprehensive systematic 
review and meta-analysis of observational studies including 
22,000 pregnant women have reported insufficient serum 
25(OH)D concentration linked to GDM and preeclampsia.37 
An observational study from Egypt on 160 pregnant women 
also reported an inverse association between glycated hemo-
globin (HbA1c) and 25(OH)D concentrations.67 The rea-
sons for these associations between vitamin D deficiency and 
GDM have yet to be determined. A randomized controlled 
trial (RCT) involving 13 partners from 10 European countries 
Vitamin D and Lifestyle intervention for gestational diabetes 
mellitus prevention study (DALI study) to assess the potential 
effects of vitamin D supplementation in pregnancy on GDM 
risk has been completed in 2013, and the results are expected 
to give insight on future evidences for long-term metabolic 
health in mother and offspring.68
Small for gestational age. Fetal growth and develop-
ment might be affected by maternal vitamin D status.69,70 Sev-
eral observational studies have observed the associations of 
higher maternal vitamin D status with lower risk of small for 
gestational age (SGA).69–72 In a population-based birth cohort 
comprising 2,274 pregnant women from the Netherlands, being 
in the lowest serum 25(OH)D quartile was associated with a 
higher risk of SGA.72 A recent meta-analyses of 31 studies have 
reported that low maternal vitamin D status is associated with 
an increased risk of SGA [pooled odds ratio for ,75 nmol/L: 
1.85 (1.52–2.16)].37 Another meta-analysis using the literature 
from 24 studies reported a quite similar effect size [odds ratio 
(,50 nmol/L): 1.52 (1.08–2.15)].38 A recent birth cohort study 
from China examining the relationship between cord blood 
25(OH)D, fetal growth, and SGA risk reported an inverted 
U-shaped association between 25(OH)D and fetal growth 
along with a moderate reduction of SGA risk with increased 
25(OH)D.73 The mechanism by which maternal serum 25(OH)
D could affect the intrauterine growth or SGA remains elusive. 
A few well-designed epidemiological studies have provided 
human evidence to support the anti-inflammatory actions of 
the serum 25(OH)D status as frequently seen in experimen-
tal conditions in animal models74,75 and, more specifically, 
the potential for vitamin D receptor (VDR) to modulate the 
placental inflammation.76 Studies using rodents as experi-
mental models have also shown an association of maternal 
and placental inflammation with fetal growth restriction.75,77 
An epidemiological study comparing cytokines in 19 women 
with normal pregnancy and 24 preeclamptic women showed 
that serum IL-8 and TNF-α concentrations were associated 
with fetal growth restriction in preeclamptic mothers.78 More 
evidence is required to understand the exact mechanism by 
which serum 25(OH)D could be causally related to reduced 
risk of SGA in neonates. As described earlier, lower vitamin D 
status of women is linked to a number of adverse health traits in 
observational studies, but these associations may not represent 
causality and could reflect several other reasons such as lack of 
adjustment for residual confounding and/or reverse causality.
Vitamin D and its Role in Fetal Development
Experimental evidence suggests that vitamin D plays a pro-
found role in fetal development through its action in human 
placental trophoblasts via the VDR and VDR signaling 
pathways. Placental trophoblasts also express cytochrome 
P450 enzymes encoded by 25-hydroxyvitamin D3 1-alpha 
hydroxylase (CYP27B1) and 1,25-dihydroxyvitamin D3 
24-hydroxylase (CYP24A1) genes.79,80 1,25(OH)2D3 in the 
placenta is involved in the regulation of hormones involved 
in pregnancy,81,82 regulation of human chorionic gonadotro-
pin expression, and secretion in synctiotrophoblast83 and in 
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the fetal glucose/insulin axis.84 In addition, calcitriol plays 
an important role in the implantation by inducing decidu-
alization and the modulation of the immune function dur-
ing gestation.85–87 For example, primary cultures of human 
decidual cells and trophoblasts treated with 1,25(OH)2D3 
(1–100 nM) showed an inhibition of granulocyte macrophage 
colony stimulating factor 2, TNF-α, and IL-6 and increases 
dose-dependent cathelicidin antimicrobial peptide (CAMP) 
production.88–90
Epidemiological Evidence for Associations Between 
Maternal Vitamin D Status and Fetal Development
A recent study on serum 25(OH)D concentrations measured 
during pregnancy at three time points suggested that higher 
vitamin D status in the third trimester leads to 47% decrease 
in preterm births.91 As discussed earlier, the review of the evi-
dence is suggesting a role of vitamin D in the regulation of 
systemic inflammation during pregnancy, with potential down-
stream implications for offspring development and health. 
Observational evidence suggests that calcitriol could modulate 
immune function in the early life, modulate fetal and postnatal 
growth, and further supports speculations on the importance of 
vitamin D status in early life programming of long-term health.
The current knowledge on the association between 
maternal vitamin D deficiency and the programming of adi-
posity is shown in Table 1. The link between the maternal 
status in vitamin D and the risk for obesity (ie, proxied by 
BMI), hypertension (proxied by blood pressure), and type 2 
diabetes (proxied by insulin resistance) has not been addressed 
in many studies, despite a potential protective role of 
vitamin D. A recent prospective birth cohort from a Spanish 
founder population (latitude 39°–43°N) has explored the link 
between maternal 25(OH)D at about 14 weeks of pregnancy 
in 2,489 mothers and growth and adiposity outcomes in off-
spring up to the age of four years. Offspring (irrespective of 
sex) born to mother with vitamin D deficiency (25(OH)D 
concentration ,  50  nmol/L) were at a higher risk of being 
overweight at one year in comparison to offspring born to 
vitamin D-sufficient mothers (concentration .  75 nmol/L). 
The association in early life remains even after adjusting for 
maternal and fetal biological (body mass index [BMI], ges-
tational weight gain, sex, and gestational age), social, and 
life style factors and could have been predicted from prena-
tal measures of fetal abdominal circumference.92 Despite the 
lack of association observed at the age of four years, the study 
warrants follow-up and replication. In particular, BMI in 
toddler–preschool age is relatively heterogeneous and analyses 
focusing on more precise adiposity windows, such as the age 
of adiposity rebound, are critically needed.
Another longitudinal study of mothers and offspring 
from the Southampton Women’s Survey (latitude 50°N) has 
reported a similar trend between vitamin D status measured 
at 34 weeks of gestation and child fat mass assayed by Dual-
energy x-ray absorptiometry scanning at birth, four years, Ta
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and six years of age.93 The authors reported that lower serum 
25(OH)D con centration was associated with greater fat mass 
at the age of six years, but the association was attenuated at 
the age of four years after adjustment for potential confound-
ers. The study also reported on the positive association between 
maternal 25(OH)D and fat mass at birth.93 The association at 
the age of six years remained significant despite correcting for 
multiple cofactors, including breast feeding duration and vita-
min D supplementation during childhood. Interestingly, the 
vitamin status at 34 weeks was robustly predicted by the sea-
son of blood sampling (Fig. 1), which raises important ques-
tion on the best way to define maternal vitamin D status in 
pregnancy.93 Results from the Amsterdam born children and 
their development (ABCD) study (Amsterdam, latitude 52°N) 
on a multiethnic population defined a linear inverse correla-
tion between maternal deficiency (vitamin D ,  30 nmol/L) 
at 13 weeks of gestational age and the risk of being small for 
gestational age. Further aside, the observation of the current 
study has shown a higher postnatal growth velocity in the 
child born to deficient mother, suggestive of postnatal catch-
up growth.94 Another study from a German (Berlin, latitude 
52°N) population of 547 singleton-bearing mothers further 
supports a link between maternal vitamin D status and off-
spring birth weight.95 This study examined birth traits of off-
spring born to mothers with severe vitamin D deficiency at 
birth [25(OH)D , 1 nmol/L] in comparison to those born to 
vitamin D-sufficient mothers (controls). In this specific case, 
the 37 offspring had a poorer Agpar defining newborn general 
health status (ie, appearance, pulse, grimace, activity, and res-
piration) scores and were in average 14% smaller in weight than 
the control infants (n = 510) and were born 10 days earlier.95 
Such an example of severe vitamin D deficiency in the mother 
has yet to be replicated in additional studies to delineate the 
underlying mechanisms and the additional confounders. How-
ever, the study was substantiated by a translational experiment 
in mice suggesting an independent risk of postnatal growth 
retardation, premature death, and impaired glucose tolerance.95 
The recent China-Anhui Birth Cohort Study (latitude 30°N) 
on 3,658 pregnant women has reported that maternal vita-
min D deficiency levels (concentration , 50 nmol/L) have a 
relative risk (RR) of SGA [RR: 6.47 (4.30–9.75)] and low birth 
weight infants [RR: 12.31 (4.47–33.89)] when compared to 
sufficient vitamin D levels (concentration  75 nmol/L) even 
after adjustment for confounders.73 Another follow-up study of 
Indian children (n = 568, latitude 12°N) at the age of 5 and 9.5 
years with maternal 25(OH)D measured at the time of deliv-
ery has shown that boys born to vitamin D deficient mothers 
(,50 nmol/L) had a higher body fat percentage and lower fat-
free mass when compared to girls at the age of 5 years but not 
at 9.5 years.96 The study has also observed that the lower mater-
nal 25(OH)D status is associated with higher insulin resistance 
at the age of 9.5 years even after adjustment of all maternal 
covariates.96 This direct link between severe vitamin D defi-
ciency and fetal outcomes has been supported by additional 
experiment in rodents, including effects on reduced placental 
weight, increased maternal corticosterone concentrations and 
impairment in placental vascular development,97 maternal 
hypertension and dysregulated placental development,98 per-
sistent inflammation, and insulin resistance in the offspring.99 
Finally, a recent systematic review and meta-analysis study 
on the effect of vitamin D supplementation during pregnancy 
have revealed that the vitamin D supplementation was associ-
ated with increased 25(OH)D concentration with positive out-
comes on birth weight and birth length.100
VDR and the Immune System
The identification of the VDR in the membranes of periph-
eral blood mononuclear cells ignited early research on vitamin 
D as a potential immune regulator.101,102 Calcitriol exerts its 
genomic actions via the VDR, which is present in many tissues 
Figure 1. Fourier analysis of maternal vitamin d status (serum 25(oh)d concentration) at 34 weeks of gestation according to the date of blood sample 
collection (from crozier et al93).
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of the body, including trophoblasts and adipocytes.80,103,104 
VDR is also expressed in monocytes, macrophages, den-
dritic cells, and activated T-cells, suggesting that vitamin D 
can affect inflammation.102 There are more than 36 cell types 
that are acted upon by 1,25(OH)2D3 via the VDR.105 Cal-
citriol, the active form of vitamin D, is involved in the up- and 
downregulation of a wide variety of genes.106,107 The studies 
of transcriptomics using microarray approaches focused on 
the protein-coding mRNAs that were regulated by the VDR, 
usually following the treatment with ligand. These studies 
quickly established the approximate size and surprising diver-
sity of the VDR transcriptome, revealing it to be highly het-
erogeneous by cell type and also time dependent.89,108
Calcitriol plays an important role in modulating the 
immune system and the active functioning of the innate, 
and adaptive immune system is affected by vitamin D 
status.109 Liu et al established that the paracrine synthesis 
of 1,25(OH)2D3 by monocytes plays an important role in 
the innate immune response against the infectious patho-
gen Mycobacterium tuberculosis.110 The study also suggested 
that with the activation of the toll-like receptor (TLR), 
VDR, and vitamin D, 1-α-hydroxylase gene expression is 
upregulated in human macrophages. They further synthe-
size CAMP/LL37 and result in the killing of M. tuberculosis 
in an intracrine fashion. The serum isolated from African-
American individuals in the study whose 25(OH)D con-
centrations were less than 30 nmol/L was more susceptible 
to tuberculosis due to nonsufficient cathelicidin messenger 
RNA induction. This suggests that low vitamin D status 
is associated with the increased vulnerability to attack by 
pathogens, suggesting the prominent role of vitamin D in 
immune signaling.110 This is further supported by an experi-
ment on isolated macrophages where vitamin D dosing was 
found to upregulate I-kappa levels and a subsequent decrease 
of nuclear NF-kappa beta (NF-κβ) activity. NF-κβ is an 
important transcription factor for inflammatory mediators, 
and the results of the study suggest that 1,25(OH)2D3 has 
an anti-inflammatory action in macrophages.107,111 In mono-
cytes and macrophages, intracrine synthesis of 1,25(OH)2D3 
stimulates bactericidal activity, whereas in dendritic cells, its 
function and maturation are suppressed.89,112,113 Calcitriol 
further enhances dendritic cells and stimulates the produc-
tion and function of T-regulatory cells, which are important 
mediators of immune tolerance.114
The innate immune system that activates the adaptive 
immune system is primarily made up of T- and B-lymphocytes.115 
In adaptive immune system, calcitriol inhibits the proliferation 
of T-lymphocyte and the differentiation and proliferation of 
B-lymphocytes and inhibits immunoglobulin production.116–119 
The differentiation of T-cells is affected by calcitriol in vitro, 
which inhibits Th1 response and stimulates the Th2 response.120 
To date, in CD4+ T-cells, 102 genes targeted by 1,25(OH)2D3 
have been recognized,121 and it is considered that the immuno-
modulatory effects of vitamin D on the Th1/Th2 response occur 
by decreasing the production of interferon-γ (IFN-γ) and IL-2 
and increasing the production of IL-4, IL-5, and IL-10 and 
shift toward Th2 response.122,123 The effects of 1,25(OH)2D3 
on B-cells are noticeable in patients with systemic lupus ery-
thematous.116 The neutrophils that are also a part of the innate 
immune system express abundant VDR. They also act in a 
similar way to monocytes in the induction of LL37 and bacte-
ricidal activity in response to 1,25(OH)2D3.124,125
Adipose Tissue and Inflammation
The obesity pandemic is increasing worldwide at a stagger-
ing rate, and the epidemic parallels the rise in the incidence 
of vitamin D insufficiency.18,126,127 A meta-analysis reported 
a significant inverse but minute correlation between higher 
BMI and serum 25(OH)D.128 Another recent (2015) sys-
tematic review and meta-analysis study examining 23 rel-
evant articles from PubMed/Medline, Web of Science, and 
Scopus databases reported a prevalence of vitamin D defi-
ciency of 35% and 24%, respectively, in obese and overweight 
individuals irrespective of age.129 There are various plausible 
hypotheses pertaining the link between a reduced vitamin D 
concentration in obese and overweight individuals that include 
limited dietary intake, reduced sun exposure due to limited 
outdoor physical activity, reduced intestinal absorption, and 
the sequestration of vitamin D in adipose tissue.128,131,132 
The association between the BMI and the vitamin D status 
is further supported from a bidirectional instrumental vari-
able approach (Mendelian randomization) and meta-analysis 
of 21 population cohorts that included up to 42,024 partici-
pants with 12 BMI-related single nucleotide polymorphisms 
(SNPs). The study concluded that for every 1 kg/m2 increase 
in BMI, serum 25(OH)D was decreased by 1.2%, and for 
every 10% increase in instrumental BMI variable, the serum 
25(OH)D decreased by 4.2% (IV estimate 95% CI: −7.1, −1.3, 
P = 0.005).3 This supports a causal link between obesity and 
lower vitamin D status, and not the reverse.3 As to whether 
the impaired vitamin D status associated with obesity can 
alter metabolic health via proinflammatory pathways remains 
to be fully discerned.18 Adipose tissue is now recognized as an 
important mediator of impaired metabolic health in relation 
to obesity, most of which can be explained by the release of 
proinflammatory mediators.132–134
For instance, the hypertrophy of the adipose organ leads 
to a reduced secretion of adiponectin and increased secre-
tion of proinflammatory mediators, namely, IL-6, TNF-α, 
IL-8, monocyte chemoattractant protein-1, and resistin.135–137 
Adipose tissue is a major determinant of IL-6 concentration 
that increases with obesity and leads to lipolysis and fatty acid 
oxidation.138,139 Interestingly, experimental studies on mouse 
3T3-L1 cell line and isolated human adipocytes have shown 
that 1,25(OH)2D3 modulates chronic inflammation in adi-
pose tissue.18 For example, research on mature adipocytes from 
our own group illustrated that 1,25(OH)2D3 could suppress 
Lipopolysaccharide-stimulated IL-6 secretion by NF-κβ 
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inflammatory pathway in a dose-dependent manner.107 The 
results were later confirmed in other experimental models using 
both mouse and human adipocytes.140–142
Epidemiological Evidence on Associations 
Between Vitamin D And Inflammation in 
Nonpregnant Adults
While experimental models clearly suggest direct effects of 
vitamin D on inflammatory pathways, epidemiological evi-
dence from human samples of both metabolically healthy 
and unhealthy individuals is equivocal at present.107 Some, 
but not all, epidemiological reports have found associations 
between proinflammatory factors and lower vitamin D status 
(see Table 2). In an observational study on 69 healthy women 
aged 25–82 years exploring the association of inflammatory 
biomarkers with vitamin D status, TNF-α showed a linear 
inverse relationship with serum 25(OH)D concentration.143 
Similar results were observed in another study on 19 healthy 
runners with TNF-α concentration (R2 = 56.5, P , 0.001).144 
Another study on 957 older adults from Northern Ireland 
aged .60 years has demonstrated significant negative correla-
tion with IL-6, CRP, IL-6/IL-10, CRP/IL-10, and TNF-α/
IL-10 ratio with serum 25(OH)D concentration.145 A similar 
inverse relationship was found between IL-6, soluble IL-6 
receptors, and serum 25(OH)D concentration in InCHI-
ANTI study on 867 older adults aged 65 years.146 Another 
cross-sectional study on 95 healthy adults from Japan, aged 
21–69 years, has showed a positive association between IL-17 
and serum 25(OH)D concentrations.147 The major limitations 
of these studies are its cross-sectional design, low sample size, 
and inclusion of individuals from wide age groups. In addition, 
the evidence from available RCTs fails to establish an effect of 
vitamin D supplementation of the modulation of inflammation 
in obese and healthy individuals. Subsequently, many analyti-
cal and methodological shortcomings have yet to be considered 
to understand in detail the physiological role of vitamin D in 
the modulation of the inflammatory stress in vivo. The analysis 
should be better corrected for a number of cofactors, allowing 
us a better capture of the life style and behavioral confound-
ing. Stratified or personalized analyses taking into account the 
gender, the age, the ethnicity, and the adiposity should also 
be considered. Finally, only a limited number of inflamma-
tory makers have been considered that limits the possibility 
to underpin the relevant metabolic pathways. Observations in 
epidemiology and animal models are suggestive of a protec-
tion of cardiometabolic status by serum 25(OH)D. It must be 
acknowledged that the relation between vitamin D and meta-
bolic health raises a large debate whether the vitamin D status 
might be simply a mere reflection of individual’s own health. 
For instance, two large-scale Mendelian randomization stud-
ies do not support a causal link between low vitamin D and 
the onset of obesity3 and incident type 2 diabetes.148 A number 
of residual confounding might explain some associations and 
warrant further well-designed research. In particular, it might Ta
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be essential to account for factors of physical fitness and well-
defined measures of insulin sensitivity to correct the effects.
Conclusion
The immune system interface between the mother and her 
fetus is essential for maintaining a healthy pregnancy, sustain-
ing maternal immunocompetence, and supporting the devel-
opment of the offspring immune system.149 One association 
study using data on 153 pregnant Indian women observed that 
altered maternal 25(OH)D could have a wide range of effects 
on regulatory T- and B-cells with IgE receptors.150 In fact, the 
placental vitamin D-deficient women was characterized by a 
downregulation of the regulatory T-cell transcription factor 
FOX3, VDR, retinoic acid receptor in comparison to control 
placenta. In contrast, CD23, CD21, and vitamin D-binding 
protein expression was upregulated by vitamin D.150 An RCT 
following 225 infants examining the association of 25(OH)D in 
cord blood in relation to innate immune response has observed 
that increasing maternal vitamin D during pregnancy and early 
life will lessen the risk of allergy induced by cytokines.151 An 
observational study from Germany evaluating the association 
of season at birth, cord blood 25(OH)D, and the markers of 
allergy (IL-10 and IgE) reported that serum 25(OH)D was 
correlated with IL-10 levels.152
The current knowledge on maternal vitamin D status 
in pregnancy and its association with metabolic and neona-
tal outcomes cannot be easily translated into guidelines for 
clinical practice due to many inconsistencies in findings and 
heterogeneity of evidence sources. The Lancet’s Nutrition 
Interventions Review Group and Maternal and Child Nutrition 
Group, which made a comprehensive literature-based analy-
sis, have identified that vitamin D status has an essential role 
in child nutrition and termed it as emerging intervention. The 
study calls for additional good-quality RCTs to support the 
findings.153 Our present review reports a lack of robust evi-
dence to support systematic vitamin D supplementation in 
pregnancy in the general population with a purpose to moder-
ate metabolic ill health. The review of the current biochemical 
evidence suggests that an empirical function for vitamin D 
has a potent modeling factor of the metabolic functions in 
human fetus. An adequate vitamin D status might act through 
various epigenetic and trophic factors to program the activity 
and the responsiveness of the metabolic organs. The current 
knowledge supports that vitamin D would act through the 
modulation of placental function and the regulation of sys-
temic inflammation. However, there remain some important 
shortcomings and methodological pitfalls to be ascertained. 
Future studies shall carefully consider the research design, 
the implementation stage, and the dose of supplementation.154 
The challenge ahead must also help to identify an interna-
tional definition of the vitamin D status that might be person-
alized according to the ethnic group, the stage of pregnancy, 
and the season. This later appears particularly challenging 
to test as both the programming of metabolic health and 
the vitamin D status are linked to specific windows with 
potential differential effect. The Finnish Vitamin D Trial 
(results expected 2020), Vitamin D and Omega-3 Trial study 
(results expected 2017), CAPS study (results expected 2015), 
Do-health (results expected 2017), and D-tect study will pro-
vide the future evidence on a long-term association between 
the vitamin D status in the early stage of the life course and 
long-term metabolic outcomes.155,156
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